176 related articles for article (PubMed ID: 20197396)
21. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
[TBL] [Abstract][Full Text] [Related]
22. Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
Azad N; Yu M; Davidson B; Choyke P; Chen CC; Wood BJ; Venkatesan A; Henning R; Calvo K; Minasian L; Edelman DC; Meltzer P; Steinberg SM; Annunziata CM; Kohn EC
Mol Cell Proteomics; 2013 Jun; 12(6):1621-31. PubMed ID: 23449826
[TBL] [Abstract][Full Text] [Related]
23. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.
Boudou-Rouquette P; Ropert S; Mir O; Coriat R; Billemont B; Tod M; Cabanes L; Franck N; Blanchet B; Goldwasser F
Oncologist; 2012; 17(9):1204-12. PubMed ID: 22752067
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
Ryan CW; Goldman BH; Lara PN; Mack PC; Beer TM; Tangen CM; Lemmon D; Pan CX; Drabkin HA; Crawford ED;
J Clin Oncol; 2007 Aug; 25(22):3296-301. PubMed ID: 17664477
[TBL] [Abstract][Full Text] [Related]
25. NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
Peereboom DM; Ahluwalia MS; Ye X; Supko JG; Hilderbrand SL; Phuphanich S; Nabors LB; Rosenfeld MR; Mikkelsen T; Grossman SA;
Neuro Oncol; 2013 Apr; 15(4):490-6. PubMed ID: 23328813
[TBL] [Abstract][Full Text] [Related]
26. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
Lim SM; Cho BC; Kim SW; Kang SY; Heo DS; Kim HT; Lee DH; Kim DW; Jung M; Choi JH; Shim HS; Choi JR; Kim JH
Lung Cancer; 2016 Mar; 93():1-8. PubMed ID: 26898607
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
[TBL] [Abstract][Full Text] [Related]
28. Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Lind JS; Meijerink MR; Dingemans AM; van Kuijk C; Ollers MC; de Ruysscher D; Postmus PE; Smit EF
Eur Radiol; 2010 Dec; 20(12):2890-8. PubMed ID: 20625738
[TBL] [Abstract][Full Text] [Related]
29. [Adverse effects of new oncologic therapies].
Weisshaupt Ch; Budak K; Pestalozzi B
Praxis (Bern 1994); 2011 Jul; 100(15):885-91; quiz 890. PubMed ID: 21792802
[No Abstract] [Full Text] [Related]
30. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
Moore M; Hirte HW; Siu L; Oza A; Hotte SJ; Petrenciuc O; Cihon F; Lathia C; Schwartz B
Ann Oncol; 2005 Oct; 16(10):1688-94. PubMed ID: 16006586
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
Cardin DB; Goff L; Li CI; Shyr Y; Winkler C; DeVore R; Schlabach L; Holloway M; McClanahan P; Meyer K; Grigorieva J; Berlin J; Chan E
Cancer Med; 2014 Jun; 3(3):572-9. PubMed ID: 24574334
[TBL] [Abstract][Full Text] [Related]
32. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
Giovannetti E; Labots M; Dekker H; Galvani E; Lind JS; Sciarrillo R; Honeywell R; Smit EF; Verheul HM; Peters GJ
Curr Pharm Des; 2013; 19(5):927-39. PubMed ID: 22973961
[TBL] [Abstract][Full Text] [Related]
33. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.
Richly H; Henning BF; Kupsch P; Passarge K; Grubert M; Hilger RA; Christensen O; Brendel E; Schwartz B; Ludwig M; Flashar C; Voigtmann R; Scheulen ME; Seeber S; Strumberg D
Ann Oncol; 2006 May; 17(5):866-73. PubMed ID: 16500908
[TBL] [Abstract][Full Text] [Related]
34. Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
Mross K; Steinbild S; Baas F; Reil M; Buss P; Mersmann S; Voliotis D; Schwartz B; Brendel E
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):618-9. PubMed ID: 14692719
[No Abstract] [Full Text] [Related]
35. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.
Strumberg D; Voliotis D; Moeller JG; Hilger RA; Richly H; Kredtke S; Beling C; Scheulen ME; Seeber S
Int J Clin Pharmacol Ther; 2002 Dec; 40(12):580-1. PubMed ID: 12503822
[No Abstract] [Full Text] [Related]
36. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
Siu LL; Awada A; Takimoto CH; Piccart M; Schwartz B; Giannaris T; Lathia C; Petrenciuc O; Moore MJ
Clin Cancer Res; 2006 Jan; 12(1):144-51. PubMed ID: 16397036
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
38. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
Flaherty KT; Schiller J; Schuchter LM; Liu G; Tuveson DA; Redlinger M; Lathia C; Xia C; Petrenciuc O; Hingorani SR; Jacobetz MA; Van Belle PA; Elder D; Brose MS; Weber BL; Albertini MR; O'Dwyer PJ
Clin Cancer Res; 2008 Aug; 14(15):4836-42. PubMed ID: 18676756
[TBL] [Abstract][Full Text] [Related]
39. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
Jilaveanu L; Zito C; Lee SJ; Nathanson KL; Camp RL; Rimm DL; Flaherty KT; Kluger HM
Clin Cancer Res; 2009 Feb; 15(3):1076-85. PubMed ID: 19188183
[TBL] [Abstract][Full Text] [Related]
40. A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
Gridelli C; Rossi A; Mongillo F; Bareschino M; Maione P; Ciardiello F
Clin Lung Cancer; 2007 May; 8(6):396-8. PubMed ID: 17562243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]